Biogen Idec may impressing Wall Street with its new Tecfidera treatment for multiple sclerosis, but the drugmaker is not impressing regulators with some of its practices for manufacturing a pair of older treatments Tysabri and Avonex. A recent ... BioSpace, 1 week ago
Biogen's Tecfidera Time-Out Pays Off - Motley Fool, 3 weeks ago
Biogen announces determination by CHMP that Dimethyl Fumarate in TECFIDERA to be a New Active Substance in the EU - Individual.com, 3 weeks ago
[at Motley Fool] ? A decision to put off the launch of Biogen's (BIIB) highly anticipated launch of its MS drug Tecfidera in Europe appears to have paid off, thanks to expanded patent protection. Read more on this. Biogen Idec Inc. (BIIB), with a ...Jutia Group, 3 weeks ago Biogen Idec Gets Regulatory Protection For MS Drug Tecfidera In Europe RTTNews.com, 3 weeks ago UPDATE 2-Biogen wins 10 years' protection for MS drug in Europe CNBC, 3 weeks ago UPDATE 1-Biogen wins vital protection for MS drug in Europe CNBC, 3 weeks ago
Biogen Idec (BIIB) Tecfidera qualifies as a "new active substance," European regulators said, which along with patents, should give Biogen the market protection it needs to begin selling the drug in Europe later this year. Biogen had put the ...TheStreet.com, 3 weeks ago Biogen's Tecfidera MS Drug Wins Additional European Protection Bloomberg, 3 weeks ago
Biogen ( BIIB ) Tecfidera sales are tracking at $363-$365M in Q4, according to Deutsche Bank, citing IMS data. "Our calculations on IMS data for Tecfidera for week ending 11/22 indicate strong Tecfidera at $363M-$365M in Q4. For FY13, our ...Seeking Alpha, 2 weeks ago Deutsche Bank Comments on How Biogen Idec May be Affected by Tecfidera IMS Data Benzinga.com, 2 weeks ago
Posted 10:58 AM ET Biogen Idec's (BIIB) multiple-sclerosis drug Tecfidera moved a step closer to launch in the European Union Friday after Biogen won a long-fought battle for market exclusivity. Biogen stock jumped more than 10% in early trading ...Investor's Business Daily, 3 weeks ago
Physician Views: As Tecfidera Approaches a Critical Juncture in Europe, How are Neurologist Perceptions Towards Biogen Idec's MS Drug Shaping Up?
Region: Global FirstWord Publishing Sales of Biogen Idec's multiple sclerosis therapy Tecfidera may continue to exceed initial expectations in the US market, but in Europe a shadow of doubt has been cast across the future of the drug. On the ...Research and Markets, 1 month ago Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance BusinessWeek, 1 month ago Biogen Idec Reports Q3 Profit Rise Drugs.com, 1 month ago Biogen Idec Profit Rises 22% on Tecfidera Sales Nasdaq, 1 month ago
"According to EMA documents, a review is going on regarding a potential data exclusivity decision and the agency looks likely to reach a conclusion by November. We expect the decision to be made public on November 22 after CHMP meeting," ...Seeking Alpha, 1 month ago
Biogen ( BIIB )beats handily on the bottom line and narrowly on the top, as net income and revenue rise 23% and 32% Y/Y, respectively. Tecfidera sales breeze past expectations, coming in at $286M versus consensus of around $218M. Tecfidera is now ...Seeking Alpha, 1 month ago
Deutsche Bank sees $7 per share upside for Biogen should the European Union grant Tecfidera exclusivity, and $5 per share downside should exclusivity not be granted. Deutsche sees $18 per share of potential downside should Biogen decide not to ...Yahoo! Finance, 1 month ago Biogen's Management Presents at the Deutsche Bank BioFEST Conference (Transcript) Seeking Alpha, 1 week ago Momenta Pharmaceuticals' CEO Presents at Deutsche Bank BioFEST Conference (Transcript) Seeking Alpha, 2 weeks ago
At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya
PR Newswire EXTON, Pa., Dec. 10, 2013 EXTON, Pa. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO ) The recently published report finds that one-fifth of Tecfidera-treated patients have experienced flushing and/or gastrointestinal ...Digital Journal, 1 week ago Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago TickerTech.com, 6 days ago Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch BusinessWeek, 3 weeks ago U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Finwin, 4 weeks ago
on your WebpageAdd Widget >Get your members hooked!